Luis Alejandro TORO-CABRERA,Luis Fernando MICHEA-ACEVEDO
申请号：
US15767708
公开号：
US20180289306A1
申请日:
2016.10.14
申请国别(地区):
US
年份:
2018
代理人:
摘要：
The invention is an ex vivo method for early detection of acute kidney injury in critical patients, which includes the measurements of fibroblast growth factor 23 (FGF23), klotho (KL) and erythropoietin (EPO) as biomarkers. These measurements are obtained from a venous blood sample or urine, and allow the determination of the following indicators: 1=([FGF23]p×[EPO]p) 2=([FGF23]p/[Klotho]p) 3=([EPO]p)/[Klotho]p) 4=([FGF23]p×[EPO]p)/[Klotho]p) where [X]p is defined as the plasma level of a specific molecule (X) which includes fibroblast growth factor 23 (FGF23), klotho (KL) or erythropoietin (EPO). If the value of the indicator 1, 2, 3, 4 or two or more thereof, is equal or higher than a cut-off point (10 U), the indicator and/or indicators allow the identification of patients with high risk of developing AKI, with a high sensitivity/specificity. Therefore high levels of the indicator are associated to a high probability of the presence/development of AKI, which allows to perform specific clinical interventions for patients with AKI. If the value of the indicator 1, 2, 3, 4 or two or more thereof, is lower than the previously mentioned cut-off point, the probability of presence/development of AKI is low, therefore patients require only standard treatment.
